Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.28B P/E - EPS this Y 33.70% Ern Qtrly Grth -
Income -506.98M Forward P/E -7.34 EPS next Y 49.90% 50D Avg Chg -9.00%
Sales 249.38M PEG 0.18 EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 7.92 EPS next 5Y -92.01% 52W High Chg -32.00%
Recommedations 2.10 Quick Ratio 3.51 Shares Outstanding 61.23M 52W Low Chg 44.00%
Insider Own 0.85% ROA -25.34% Shares Float 60.55M Beta 0.65
Inst Own 107.95% ROE -157.14% Shares Shorted/Prior 4.25M/5.15M Price 54.30
Gross Margin 94.87% Profit Margin -203.30% Avg. Volume 721,614 Target Price 97.38
Oper. Margin -146.07% Earnings Date May 2 Volume 3,157,311 Change -15.34%
About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation News
04/25/24 Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
04/18/24 Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
04/11/24 Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
04/04/24 Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/29/24 Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?
03/28/24 Insiders Are Dumping These 10 Healthcare Stocks
03/22/24 CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
03/21/24 Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
03/17/24 30 Biggest Biotechnology Companies in the World
03/15/24 Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares
03/12/24 Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
03/06/24 Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
02/23/24 Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
02/17/24 Blueprint Medicines Full Year 2023 Earnings: Beats Expectations
02/16/24 Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
02/16/24 Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript
02/16/24 Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
02/15/24 Q4 2023 Blueprint Medicines Corp Earnings Call
02/15/24 Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat
02/15/24 Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
BPMC Chatroom

User Image FlynancialAnalyst Posted - 9 hours ago

$BPMC $5.56B mc $XBI $IBB name holding up extremely well versus the rest of the space, just under key $100 level. 40/80 wk SMAs in firm uptrends Fully institutionally owned

User Image RonIsWrong Posted - 20 hours ago

$BPMC On April 25, 2024, Blueprint Medicines Corporation (the “Company”) held a webinar focused on emerging opportunities for mast cell-targeted therapies and the Company’s approach to modulating mast cells and building a pipeline in allergic and inflammatory diseases. Certain selected presentation materials used during the webinar are attached : http://archive.fast-edgar.com/20240425/AQBZC22C8Z22STZ222JH2ZZZM8WBZ2V2DL62/tm2412692d1_ex99-1.htm

User Image Doozio Posted - 1 day ago

$BPMC chop chop huckleberries…..

User Image RonIsWrong Posted - 2 days ago

$BPMC gearing up

User Image biochirp Posted - 3 days ago

$BPMC ER should be good

User Image Stock_Titan Posted - 1 week ago

$BPMC Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 https://www.stocktitan.net/news/BPMC/blueprint-medicines-to-report-first-quarter-2024-financial-results-9yca99klyl62.html

User Image US_Bull Posted - 1 week ago

$BPMC Hoping to cash out at AUPH and reenter this under the radar gem has made me good money previously there is no way these guys aren't BO in the next not so distant future.

User Image biochirp Posted - 1 week ago

$BPMC you'd think revenue stage pharma would do better in a high interest rate environment

User Image Stock_Titan Posted - 2 weeks ago

$BPMC Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics https://www.stocktitan.net/news/BPMC/blueprint-medicines-to-host-webcast-and-conference-call-highlighting-5mm027volc4y.html

User Image tedevan Posted - 2 weeks ago

$SNDX $BPMC $IOVA $SWTX $IMCR

User Image Night_Owl_Biotech Posted - 2 weeks ago

With Morgan Stanley in the news again about M&A & bio valuations with rate cuts, attached is a list of all of the commercial-stage oncology focused bios that have been acquired or merged/spun-off showing the # of months the LLE took place after its last FDA approval (sorted low to high). On the right side please find the remaining independent commercial-stage oncology focused biopharmas noting how long it has been since FDA approval. Be careful, our date info may not be perfect with those that have/had multiple FDA approvals. If commercial-stage oncology focused M&A is expected to be hot this year (versus clinical-stage) then it appears there are only so many with market caps of less than $10B & a recent approval (enough to drive significant growth to an acquirer). Obvious candidates would be $SWTX $IOVA $IMCR $SNDX & $BPMC

User Image Stock_Titan Posted - 3 weeks ago

$BPMC Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-bj7brzd7e9pv.html

User Image RonIsWrong Posted - 3 weeks ago

$BPMC going the right way

User Image chartsmarter Posted - 03/28/24

FULL BIOTECH GAME PLAN UP: https://www.chartsmarter.com/2024/03/28/healthcare-sector-review-4-1-24/ "once a month we show what we do daily. XBI needs to hold above very round 90 number. $IOVA reclaims 21-day EMA, $BPMC eyeing par, $AGIO puts in doji candle Thursday." $CRSP $BEAM TWST OSCR #biotech #StockMarket

User Image RonIsWrong Posted - 03/27/24

$BPMC 👀

User Image RonIsWrong Posted - 03/27/24

$BPMC getting a little fun here today? still long.

User Image Doozio Posted - 03/27/24

$BPMC wen 🧠⏰?

User Image insiderbuyingselling Posted - 4 weeks ago

$BPMC new insider selling: 11033 shares. http://insiderbuyingselling.com/?t=BPMC

User Image insiderbuyingselling Posted - 1 month ago

$BPMC new insider selling: 25073 shares. http://insiderbuyingselling.com/?t=BPMC

User Image insiderbuyingselling Posted - 1 month ago

$BPMC new insider selling: 4377 shares. http://insiderbuyingselling.com/?t=BPMC

User Image Stock_Titan Posted - 1 month ago

$BPMC Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-5i8otqk5txtl.html

User Image insiderbuyingselling Posted - 1 month ago

$BPMC new insider selling: 621 shares. http://insiderbuyingselling.com/?t=BPMC

User Image StupediaTrades Posted - 1 month ago

$BPMC

User Image insiderbuyingselling Posted - 1 month ago

$BPMC new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=BPMC

User Image wallstreetcorruption Posted - 02/29/24

$ntla to $36 today. $crsp $BPMC $BTC.X kathy woods keeps loading

User Image wallstreetcorruption Posted - 02/28/24

$NTLA this is def headed to $60. They have a billion in cash and $REGN as a partner. $CRSP $BTC.X $BPMC

User Image RonIsWrong Posted - 02/28/24

$BPMC $100 !

User Image MaverikIT Posted - 02/27/24

@net0trader @IsabellaDC @RonIsWrong @Wigglyick @Im_not_Mr_Lebowski @Cash4freedom Ron, your $BPMC - tagging on

User Image RonIsWrong Posted - 02/27/24

$BPMC uh oh... getting really close!

User Image RonIsWrong Posted - 02/27/24

$BPMC get it!!

Analyst Ratings
JMP Securities Market Outperform Apr 10, 24
Needham Buy Feb 26, 24
JMP Securities Market Outperform Feb 16, 24
Citigroup Sell Feb 16, 24
Barclays Equal-Weight Feb 13, 24
JMP Securities Market Outperform Jan 16, 24
Stifel Buy Jan 9, 24
Raymond James Strong Buy Dec 22, 23
Wells Fargo Overweight Dec 19, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Albers Jeffrey W. Director Director Jan 25 Sell 82.3 25,000 2,057,500 176,050 01/29/24
Albers Jeffrey W. Director Director Jan 25 Option 8.44 25,000 211,000 201,050 01/29/24
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 22 Sell 90 714 64,260 14,324 12/26/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 22 Option 8.8 714 6,283 15,038 12/26/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 15 Sell 84.35 3,914 330,146 14,324 12/19/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 15 Option 1.87 3,654 6,833 16,411 12/19/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 07 Sell 75 5,000 375,000 24,495 12/11/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 07 Option 54.13 5,000 270,650 29,495 12/11/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 04 Sell 71.43 600 42,858 24,495 12/06/23
Albers Jeffrey W. Director Director Nov 24 Sell 67.53 15,000 1,012,950 176,050 11/28/23
Albers Jeffrey W. Director Director Nov 24 Option 1.87 15,000 28,050 191,050 11/28/23
Albers Jeffrey W. Director Director Nov 01 Option 36.05 10,000 360,500 177,535 11/03/23
Albers Jeffrey W. Director Director Nov 01 Sell 60.39 10,000 603,900 176,050 11/03/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Oct 26 Sell 56.40 600 33,840 25,095 10/30/23
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Oct 04 Sell 48.06 3,769 181,138 62,080 10/05/23
Albers Jeffrey W. Director Director Sep 27 Sell 49.86 25,000 1,246,500 176,050 09/29/23
Albers Jeffrey W. Director Director Sep 27 Option 1.87 25,000 46,750 182,948 09/29/23
Albers Jeffrey W. Director Director Aug 24 Sell 49.87 25,000 1,246,750 176,050 08/28/23
Albers Jeffrey W. Director Director Aug 24 Option 1.87 25,000 46,750 186,050 08/28/23
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jun 05 Sell 52.06 2,307 120,102 38,117 06/07/23
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Jun 05 Sell 52.05 1,404 73,078 36,878 06/07/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Mar 06 Sell 45.01 1,875 84,394 25,695 03/08/23
Rossi Christina CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Mar 06 Sell 45 3,059 137,655 55,376 03/08/23
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Mar 06 Sell 45.04 1,948 87,738 65,849 03/08/23
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Mar 06 Sell 45.25 1,514 68,508 38,282 03/08/23
Lee Philina CHIEF COMMERCIAL OFF.. CHIEF COMMERCIAL OFFICER Mar 06 Sell 45.06 1,676 75,521 31,178 03/08/23
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Mar 06 Sell 45.01 3,158 142,142 50,178 03/08/23
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 06 Sell 45.25 761 34,435 40,424 03/08/23
Albers Jeffrey W. Director Director Mar 06 Sell 45 9,793 440,685 173,450 03/08/23
McCain Tracey L EVP AND CHIEF LEGAL.. EVP AND CHIEF LEGAL OFFICER Mar 06 Sell 45.07 3,322 149,723 52,666 03/08/23
Landsittel Michael CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Mar 06 Sell 45.1 3,007 135,616 48,523 03/08/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Mar 06 Sell 45.06 1,126 50,738 14,175 03/08/23
Haviland Kate CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Mar 06 Sell 45.19 6,640 300,062 125,641 03/08/23
Albers Jeffrey W. Director Director Dec 05 Option 8.44 20,000 168,800 203,243 12/07/22
Albers Jeffrey W. Director Director Dec 05 Sell 50.09 20,000 1,001,800 183,243 12/07/22
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Oct 04 Sell 67.30 3,477 234,002 52,797 10/05/22
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Aug 24 Option 15.01 5,000 75,050 45,836 08/26/22
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Aug 24 Sell 75.11 5,000 375,550 40,836 08/26/22
Albers Jeffrey W. Director Director Aug 19 Option 15.01 10,000 150,100 191,653 08/23/22
Albers Jeffrey W. Director Director Aug 19 Sell 70.6 10,000 706,000 183,243 08/23/22
Albers Jeffrey W. Director Director Aug 16 Option 8.44 20,000 168,800 203,243 08/18/22
Albers Jeffrey W. Director Director Aug 16 Sell 68.72 20,000 1,374,400 183,243 08/18/22
Albers Jeffrey W. Director Director Aug 08 Option 5.34 10,000 53,400 193,243 08/10/22
Albers Jeffrey W. Director Director Aug 08 Sell 70.07 10,000 700,700 183,243 08/10/22
Murray Christopher K. SVP, TECHNICAL OPERA.. SVP, TECHNICAL OPERATIONS Aug 04 Sell 62.72 5,000 313,600 18,820 08/08/22
Demetri George Director Director Jun 21 Buy 82.66 10 827 5,822 06/30/22
Demetri George Director Director Jun 21 Sell 58.56 10 586 5,812 06/30/22
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jun 06 Sell 59.76 1,908 114,022 28,685 06/08/22
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Jun 06 Sell 59.88 4,375 261,975 27,296 06/08/22
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Mar 03 Sell 58.23 1,017 59,220 11,955 03/08/22